PT912184E - Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina - Google Patents

Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina

Info

Publication number: PT912184E
Authority: PT; Portugal
Prior art keywords: derivative; sietma; citoquine; diseases; central
Prior art date: 1996-06-25

Application number

PT97930203T

Other languages

English (en)

Inventor

Matthew S Miller

Ernest Knight Jr

Thomas M Engber

Forrest A Haun

Michael S Saporito

Lisa D Aimone

Original Assignee

Cephalon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-25

Filing date

1997-06-24

Publication date

2002-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21798468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT912184(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-24 Application filed by Cephalon Inc filed Critical Cephalon Inc

2002-12-31 Publication of PT912184E publication Critical patent/PT912184E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Immunology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT97930203T 1996-06-25 1997-06-24 Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina PT912184E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2040696P	1996-06-25	1996-06-25

Publications (1)

Publication Number	Publication Date
PT912184E true PT912184E (pt)	2002-12-31

Family

ID=21798468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97930203T PT912184E (pt)	1996-06-25	1997-06-24	Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina

Country Status (16)

Country	Link
US (1)	US6184217B1 (pt)
EP (1)	EP0912184B1 (pt)
JP (2)	JP2000514420A (pt)
CN (1)	CN1108799C (pt)
AT (1)	ATE224718T1 (pt)
AU (1)	AU721942B2 (pt)
BR (1)	BR9710693A (pt)
DE (1)	DE69715862T2 (pt)
DK (1)	DK0912184T3 (pt)
ES (1)	ES2184106T3 (pt)
NO (1)	NO317335B1 (pt)
NZ (1)	NZ333441A (pt)
PT (1)	PT912184E (pt)
RU (1)	RU2183959C2 (pt)
UA (1)	UA65542C2 (pt)
WO (1)	WO1997049406A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6127401A (en) *	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
US6200968B1 (en) *	1998-08-06	2001-03-13	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
KR100628847B1 (ko)	1998-09-25	2006-09-29	세파론, 인코포레이티드	감각 유모 세포 및 와우 뉴런의 손상의 예방 또는 치료 방법
CA2347519A1 (en)	1998-10-13	2000-04-20	Kyowa Hakko Kogyo Co., Ltd.	An agent for treating ophthalmopathy
JP2000290184A (ja) *	1999-04-01	2000-10-17	Kyowa Hakko Kogyo Co Ltd	経鼻投与製剤
CA2396165C (en) *	2000-01-14	2011-01-04	John F. Hunt	Airway alkalinization as therapy for airway diseases
AU2001261324A1 (en) *	2000-05-08	2001-11-20	Psoriasis Research Institute	Psoriasis treatment
US7129250B2 (en)	2000-05-19	2006-10-31	Aegera Therapeutics Inc.	Neuroprotective and anti-proliferative compounds
US7018999B2 (en)	2001-05-16	2006-03-28	Cephalon, Inc.	Methods for the treatment and prevention of pain
AU2003300397A1 (en) *	2002-12-23	2004-07-22	Rinat Neuroscience Corp.	Methods for treating taxol-induced sensory neuropathy
ES2537015T3 (es)	2003-03-19	2015-06-01	Biogen Ma Inc.	Proteína de unión del receptor de NOGO
WO2004084836A2 (en) *	2003-03-20	2004-10-07	Rinat Neuroscience Corp.	Methods for treating taxol-induced gut disorder
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
MXPA06000514A (es) *	2003-07-14	2006-06-20	Decode Genetics Ehf	Metodos de diagnostico y tratamiento del asma y otras enfermedades respiratorias basandose en la asociacion de haplotipos.
EP1653972A1 (en) *	2003-07-23	2006-05-10	Creabilis Therapeutics s.r.l.	Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
WO2005082920A1 (en)	2004-02-27	2005-09-09	H. Lundbeck A/S	Crystalline forms of a pharmaceutical compound
EP1776136B1 (en)	2004-06-24	2012-10-03	Biogen Idec MA Inc.	Treatment of conditions involving demyelination
MX2007001155A (es) *	2004-07-29	2007-08-14	Creabilis Therapeutics Spa	Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
AR054260A1 (es) *	2005-04-26	2007-06-13	Rinat Neuroscience Corp	Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
DK1904104T3 (da)	2005-07-08	2013-11-11	Biogen Idec Inc	SP35-antistoffer og anvendelser heraf
WO2008013782A2 (en)	2006-07-24	2008-01-31	Biogen Idec Ma Inc.	Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
AU2009269099B2 (en)	2008-07-09	2016-03-10	Biogen Ma Inc.	Compositions comprising antibodies to LINGO or fragments thereof
CA2873623C (en)	2012-05-14	2021-11-09	Biogen Idec Ma Inc.	Lingo-2 antagonists for treatment of conditions involving motor neurons
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041489A (ja) *	1983-08-12	1985-03-05	Kyowa Hakko Kogyo Co Ltd	新規生理活性物質ｋ―２５２
US4554402A (en)	1983-12-23	1985-11-19	Aluminum Company Of America	Vibration damper for overhead conductor
JPS62120388A (ja)	1985-11-19	1987-06-01	Meiji Seika Kaisha Ltd	Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja)	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja)	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja)	1986-03-20	1987-09-28	Kyowa Hakko Kogyo Co Ltd	新規物質ｕｃｎ―０１
US4816450A (en)	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja)	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US4735939A (en)	1987-02-27	1988-04-05	The Dow Chemical Company	Insecticidal activity of staurosporine
US4923986A (en)	1987-03-09	1990-05-08	Kyowa Hakko Kogyo Co., Ltd.	Derivatives of physiologically active substance K-252
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en)	1987-06-15	1988-11-30	Ciba Geigy Ag	Derivatives substituted at methyl-amino nitrogen
JPH07113027B2 (ja)	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体
WO1989007105A1 (fr)	1988-02-04	1989-08-10	Kyowa Hakko Kogyo Co., Ltd.	Derives de staurosporine
DE3835842A1 (de)	1988-10-21	1990-04-26	Goedecke Ag	Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de)	1989-07-25	1991-01-31	Goedecke Ag	Indolocarbazol und dessen verwendung
WO1991009034A1 (en)	1989-12-14	1991-06-27	Schering Corporation	Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja)	1991-03-04	1993-04-06	Rikagaku Kenkyusho	新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
WO1993008809A1 (en)	1991-11-08	1993-05-13	The University Of Southern California	Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja)	1991-12-13	1997-03-19	伊藤ハム株式会社	ウシ胚の性の識別方法
RU2045575C1 (ru) *	1992-01-29	1995-10-10	Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов	Рекомбинатная плазмидная днк ppr - tgatg - hil - 1 beta - tsr, обеспечивающая синтез рекомбинантного интерлейкина-1 и штамм escherichia coli - продуцент рекомбинантного интерлейкина-1 бета человека
US6271242B1 (en)	1992-02-10	2001-08-07	Bristol-Myers Squibb Co.	Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja)	1992-03-03	1993-09-24	Meiji Seika Kaisha Ltd	スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
DE69326388T2 (de)	1992-06-22	1999-12-30	Kyowa Hakko Kogyo Co., Ltd.	Verfahren zur Herstellung von Staurosporin-Derivaten
JPH0673063A (ja)	1992-06-22	1994-03-15	Kyowa Hakko Kogyo Co Ltd	Ｕｃｎ−０１誘導体
US5621100A (en)	1992-07-24	1997-04-15	Cephalon, Inc.	K-252a derivatives for treatment of neurological disorders
US5461146A (en) *	1992-07-24	1995-10-24	Cephalon, Inc.	Selected protein kinase inhibitors for the treatment of neurological disorders
GB9215921D0 (en) *	1992-07-27	1992-09-09	Wellcome Found	Anti-inflammatory compounds
WO1994027982A1 (en)	1993-05-28	1994-12-08	Cephalon, Inc.	Use of indolocarbazole derivatives to treat a pathological condition of the prostate
JPH08511785A (ja)	1993-06-17	1996-12-10	チバ−ガイギーアクチェンゲゼルシャフト	プロテインキナーゼｃ阻害剤として有用なインドロカルバゾール
AU1911095A (en) *	1994-02-18	1995-09-04	Cephalon, Inc.	Aqueous indolocarbazole solutions

1997
- 1997-06-24 WO PCT/US1997/010898 patent/WO1997049406A1/en not_active Ceased
- 1997-06-24 CN CN97197341A patent/CN1108799C/zh not_active Expired - Lifetime
- 1997-06-24 PT PT97930203T patent/PT912184E/pt unknown
- 1997-06-24 EP EP97930203A patent/EP0912184B1/en not_active Expired - Lifetime
- 1997-06-24 AT AT97930203T patent/ATE224718T1/de active
- 1997-06-24 NZ NZ333441A patent/NZ333441A/xx not_active IP Right Cessation
- 1997-06-24 AU AU34090/97A patent/AU721942B2/en not_active Expired
- 1997-06-24 BR BR9710693-3A patent/BR9710693A/pt not_active IP Right Cessation
- 1997-06-24 UA UA99010342A patent/UA65542C2/uk unknown
- 1997-06-24 RU RU99101117/14A patent/RU2183959C2/ru active
- 1997-06-24 ES ES97930203T patent/ES2184106T3/es not_active Expired - Lifetime
- 1997-06-24 DK DK97930203T patent/DK0912184T3/da active
- 1997-06-24 JP JP10503444A patent/JP2000514420A/ja active Pending
- 1997-06-24 DE DE69715862T patent/DE69715862T2/de not_active Expired - Lifetime
- 1997-06-24 US US08/881,679 patent/US6184217B1/en not_active Expired - Lifetime
1998
- 1998-12-23 NO NO19986111A patent/NO317335B1/no not_active IP Right Cessation
2008
- 2008-03-04 JP JP2008053174A patent/JP4767982B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2000514420A (ja)	2000-10-31
BR9710693A (pt)	2000-01-11
EP0912184B1 (en)	2002-09-25
UA65542C2 (uk)	2004-04-15
AU721942B2 (en)	2000-07-20
JP2008189676A (ja)	2008-08-21
EP0912184A1 (en)	1999-05-06
HK1018745A1 (en)	2000-01-07
CN1108799C (zh)	2003-05-21
RU2183959C2 (ru)	2002-06-27
CN1228024A (zh)	1999-09-08
DE69715862D1 (de)	2002-10-31
ATE224718T1 (de)	2002-10-15
ES2184106T3 (es)	2003-04-01
NO986111D0 (no)	1998-12-23
NO986111L (no)	1999-02-23
US6184217B1 (en)	2001-02-06
NZ333441A (en)	1999-05-28
JP4767982B2 (ja)	2011-09-07
WO1997049406A1 (en)	1997-12-31
DK0912184T3 (da)	2002-11-25
AU3409097A (en)	1998-01-14
NO317335B1 (no)	2004-10-11
DE69715862T2 (de)	2003-04-10

Publication	Publication Date	Title
PT912184E (pt)	2002-12-31	Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
UA66825C2 (uk)	2004-06-15	Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BR0206633A (pt)	2004-02-17	Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
ATE297208T1 (de)	2005-06-15	Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
NO990433L (no)	1999-03-25	Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
BR0215151A (pt)	2004-10-19	Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
BR0209056A (pt)	2004-08-10	Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
ATE357438T1 (de)	2007-04-15	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0215222A (pt)	2005-05-24	Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6
MXPA02012626A (es)	2003-04-25	Bis-arilsufonas.
BRPI0412809A (pt)	2006-09-26	compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
HUP9802091A2 (hu)	1998-12-28	Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
PT730865E (pt)	2002-04-29	Utilizacao de bloqueadores dos receptores de serotonina e dopamina para o tratamento de perturbacoes mentais associadas a doencas cerebrovasculares
ES2191449T3 (es)	2003-09-01	Derivados de ciclopentabenzofurano y su uso.
ES2166830T3 (es)	2002-05-01	Derivados 2,7-sustituidos de octahidro-1h-pirido(1,2-a)pirazina.
PT845988E (pt)	2002-05-31	Novas isoquinolinas fundidas como ligandos do receptor da dopamina
NO20005757L (no)	2000-11-14	Cabergolin og pramipexol - nye anvendelser og kombinasjoner
ECSP003590A (es)	2002-02-25	Compuestos calcioliticos
AU2002227895A1 (en)	2002-05-15	Sulphonamides for the treatment of central nervous system diseases
ATE256126T1 (de)	2003-12-15	5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
NO984651L (no)	1998-12-03	Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
ES1022449Y (es)	1993-10-01	Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
NO20012538L (no)	2001-07-04	Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
CA2258662A1 (en)	1997-12-31	Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
DE59103080D1 (de)	1994-11-03	9-Amino-2-phenylbicyclo[3.3.1]nonane und 9-Amino-2-phenylbicyclo[3.3.1]-non-2-ene und diese enthaltende therapeutische Mittel.